Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Euglena Co., Ltd. (2931:JPX), powered by AI.
Euglena Co., Ltd. is currently trading at ¥338. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Euglena Co., Ltd. on Alpha Lenz.
Euglena Co., Ltd.'s P/E ratio is -57.3.
“Euglena Co., Ltd. trades at a P/E of -57.3 (undervalued) with modest ROE of -2.6%.”
Ask for details →Euglena Co., Ltd. is a biotechnology company that primarily focuses on the research, development, and commercialization of products derived from euglena, a type of microalgae. This asset is integral in the biofuels, nutrition, and cosmetics industries, leveraging the high nutritional value and diverse applications of euglena. The company's offerings include health foods and supplements, as well as environmentally friendly biofuels, showcasing its commitment to sustainability and innovative solutions. Established with a forward-thinking approach, Euglena Co., Ltd. plays a significant role in promoting alternative energy sources and contributing to health and wellness markets. By harnessing the unique properties of euglena, the company not only supports the growing demand for sustainable products but also advances efforts in reducing the carbon footprint associated with traditional energy and consumer products. With its headquarters in Tokyo, Japan, Euglena Co., Ltd. continues to expand its impact across various sectors, enhancing its market presence and contributing to environmental and health-focused initiatives worldwide.
“Euglena Co., Ltd. trades at a P/E of -57.3 (undervalued) with modest ROE of -2.6%.”
Ask for details →Euglena Co., Ltd. (ticker: 2931) is a company listed on JPX in the Consumer Defensive sector (Household & Personal Products). It has approximately 897 employees. Market cap is $46.1B.
The current price is 338 with a P/E ratio of -57.29x and P/B of 1.49x.
ROE is -2.57% and operating margin is 6.20%. Annual revenue is $50.4B.